Bipolar Disorder

Have you had difficulty with differential diagnosis when patients have manic symptoms and psychosis? One doctor discusses the related DSM-5 criteria changes and some of their implications for psychopharmacology.

Patients weigh in on their experiences living with and receiving treatment for the disorder.

Caplyta is now FDA-approved for depressive episodes from bipolar I and II.

This infrequent, but important, toxic effect of lithium deserves increased awareness.

Need a recap of the custom Around the Practice video program on bipolar disorder? We've got you covered.

Don't fall into the trap of these 3 myths about mania in bipolar disorder...

Major depressive episode and bipolar disorders: same DSM-5 diagnostic criteria, but very different disorders.

Michael E. Thase, MD; Theresa Cerulli, MD; Gustavo Alva, MD, DFAPA; and Tina Matthews-Hayes, DNP, FNP, PMHNP, provide insight on the role of telemedicine in improving outcomes for patients with bipolar disorder.

A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.

Michael E. Thase, MD, presents the case of a 47-year-old man with treatment resistant bipolar depression.

Psychiatric experts consider mood stabilizers when treating bipolar disorder and review the role of antidepressants in disease management.

Theresa Cerulli, MD, and Tina Matthew-Hayes, DNP, FNP, PMHNP, review diagnostic difficulties of the patient’s primary care physician in patient case #1 and share optimal approaches to the diagnosis and treatment for patients with bipolar disorder.

Tina Matthews-Hayes, DNP, FNP, PMHNP, comments on screening tools for bipolar disorder and Gustavo Alva, MD, DFAPA, shares his impressions from patient case #1.

A panel of experts in psychiatry share insights on the challenges and importance of making an accurate diagnosis of bipolar disorder.

Experts in psychiatry review the case of a 27-year-old woman who presents for evaluation of a complex depressive disorder.

Caplyta shows promise as a monotherapy for patients with bipolar I or bipolar II disorder experiencing a major depressive episode

At the Annual Psychiatric Times World CME Conference, an all-star lineup of presenters will share their latest research. Check out this preview of the full agenda.

Bipolar disorder and pregnancy: what considerations need to be kept in mind?

What are the greatest unmet mental health needs in the United States today? Recent statistics from the Centers for Disease Control may hold the answers.

A rare robust finding from a study on bipolar depression.

This combination treatment of olanzapine and samidorphan caused significantly less weight gain in patients with schizophrenia and bipolar I disorder.

There is debate whether schizoaffective disorder is a separate illness or is part of the continuum of schizophrenia and mood disorder spectrum.

This treatment for agitation associated with schizophrenia and bipolar disorder is moving up the FDA ladder…

A preview of 3 pivotal trials suggests promising results, but there are reasons to wait before jumping in with this antipsychotic.

Why does prazosin appear to be the safest and most effective medication for select patients with comorbid PTSD?

“As soon as Lexi reaches home, she abruptly sinks into depression and curls up in a fetal position, almost catatonic in her bed.”

Some mood episodes are more anxiety-provoking than others, and at the top of the list are mixed states.

A quick primer on nomenclature, issues to consider, and switching.

Prazosin appears to be effective and perhaps the best medication for selected patients, including those with bipolar disorder.